<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04191824</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00102997</org_study_id>
    <nct_id>NCT04191824</nct_id>
  </id_info>
  <brief_title>Genetic Testing to Understand and Address Renal Disease Disparities Across the United States</brief_title>
  <acronym>GUARDD-US</acronym>
  <official_title>Genetic Testing to Understand and Address Renal Disease Disparities Across the United States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim is to determine the effect of participant and provider knowledge of a&#xD;
      positive APOL1 status and accompanying guideline based clinical decision support (CDS) on&#xD;
      blood pressure management on change in systolic blood pressure (SBP) from baseline to 3&#xD;
      months after randomization among the APOL1 positive participants. Secondary aims are to:&#xD;
&#xD;
        1. Determine the effect of participant and provider knowledge of a positive APOL1 status on&#xD;
           the probability of appropriate CKD diagnosis.&#xD;
&#xD;
        2. Determine the effect of participant and provider knowledge of a positive APOL1 status on&#xD;
           the probability of receiving a urine microalbumin/creatinine testing and ACE-I/ARB&#xD;
           prescription based on results of the urine microalbumin level.&#xD;
&#xD;
        3. Explore cost effectiveness, mediators, moderators, psychobehavioral impact of results&#xD;
           disclosure on participants, and effects of participant and provider knowledge of APOL1&#xD;
           status on provider treatment recommendations.&#xD;
&#xD;
      PGX Substudy&#xD;
&#xD;
      In addition, GUARDD-US will include a substudy to determine the effect of knowledge of&#xD;
      genetic test results that predict efficacy of various antihypertensive medications on change&#xD;
      in SBP from baseline to 3 months in APOL1 negative individuals.&#xD;
&#xD;
      Approximately 5,435 participants of African ancestry age 18-70 with hypertension that either:&#xD;
      1) do not have diabetes and do not have CKD, or 2) have CKD. Participants with diabetes may&#xD;
      be included as long as they also have CKD.&#xD;
&#xD;
      Population for Main Study:&#xD;
&#xD;
      Participants from Randomized Population (above) who test positive for APOL1&#xD;
&#xD;
      Population for PGx Substudy:&#xD;
&#xD;
      Participants from Randomized Population (above) randomized to Intervention and who test&#xD;
      negative for APOL1&#xD;
&#xD;
      Main Study Analyses:&#xD;
&#xD;
        -  To determine the effect of participant and provider knowledge of a positive APOL1 status&#xD;
           on SBP, we will compare the change in SBP from baseline to 3 months of the Intervention&#xD;
           - APOL1 positive group to the change in SBP from baseline to 3 months of the Control -&#xD;
           APOL1 positive group using a two sided Mann Whitney test, as appropriate, with a&#xD;
           two-sided type I error of 0.05.&#xD;
&#xD;
        -  The effect of knowledge of a positive APOL1 status on all secondary endpoints will be&#xD;
           compared between Intervention - APOL1 positives to Control - APOL1 positives with the&#xD;
           proportion difference test.&#xD;
&#xD;
        -  Additional analyses will include analysis of time trends in SBP, subset analyses, and&#xD;
           exploratory analyses of cost effectiveness, mediators, moderators, psychobehavioral&#xD;
           impact of results disclosure on participants, and effects of knowledge of APOL1 status&#xD;
           on provider treatment recommendations.&#xD;
&#xD;
      Substudy Analyses:&#xD;
&#xD;
      All primary and secondary endpoint analyses conducted for the APOL1 main study will be&#xD;
      repeated for the PGx substudy focusing on differences in outcomes between APOL1 negative&#xD;
      individuals with immediate PGx ROR (PGx Intervention) and APOL1 negative individuals with&#xD;
      delayed PGx ROR (PGx Control).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Immediate versus delayed return of Apolipoprotein L1 (APOL1) gene testing results to provider and participant.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in systolic blood pressure from baseline to 3 months</measure>
    <time_frame>Baseline to 3 month study visit</time_frame>
    <description>Change in systolic blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in urine microalbuminuria/proteinuria</measure>
    <time_frame>From baseline to 6 months</time_frame>
    <description>Change in urine microalbuminuria/proteinuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appropriate order of microalbuminuria/proteinuria tests</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Appropriate order of microalbuminuria/proteinuria tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in appropriate diagnosis for stage 3 CKD</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Change in appropriate diagnosis for stage 3 CKD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appropriate diagnosis of CKD stage 3 and above</measure>
    <time_frame>baseline to 6 months</time_frame>
    <description>Appropriate diagnosis of CKD stage 3 and above</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in appropriate diagnosis for any stage CKD</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Change in appropriate diagnosis for any stage CKD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appropriate diagnosis of all stage CKD</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>Appropriate diagnosis of all stage CKD</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5435</enrollment>
  <condition>Renal Disease</condition>
  <arm_group>
    <arm_group_label>Immediate Return of Results</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediate return of results to inform participant of APOL1 status (either positive or negative).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed Return of Results</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Delayed return of results of APOL1 status (either positive or negative) after the completion of the 6 month final study visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>APOL1 status</intervention_name>
    <description>Participants will be randomized to immediate versus delayed return of results for positive or negative APOL1 status.</description>
    <arm_group_label>Delayed Return of Results</arm_group_label>
    <arm_group_label>Immediate Return of Results</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  African American/Black&#xD;
&#xD;
          -  English Speaking&#xD;
&#xD;
          -  Age 18-70 years&#xD;
&#xD;
          -  Have diagnosis of hypertension&#xD;
&#xD;
        Diagnosis of hypertension is defined by either:&#xD;
&#xD;
          -  ICD10 diagnosis codes (i.e., I10; I11.x; I12.x; I13.x; I16.x) OR&#xD;
&#xD;
          -  On active antihypertensive therapy for indication of hypertension OR&#xD;
&#xD;
          -  Having systolic blood pressure of 140 mm Hg or greater in at least 2 of the last 3&#xD;
             consecutive recorded values in the EHR OR&#xD;
&#xD;
          -  Having hypertension in the patient's medical record problem list&#xD;
&#xD;
               -  Have been seen at ≥1 time in past year at a participating primary care site&#xD;
&#xD;
               -  Either: 1) do not have diabetes and do not have CKD, or 2) have CKD;&#xD;
&#xD;
        Participants with diabetes may be included as long as they also have CKD.&#xD;
&#xD;
          -  CKD is defined by either:&#xD;
&#xD;
             1) ICD10 codes (i.e., N18.x; E08.22; E09.22; E10.22; E11.22;E13.22 (exclude Z94.0;&#xD;
             N18.6; Z99.2)) OR&#xD;
&#xD;
          -  15 ≤ eGFR ≤ 60 ml/min for 2 time periods ≥ 3 months&#xD;
&#xD;
          -  Diabetes is defined by:&#xD;
&#xD;
          -  HbA1c ≥ 6.5 at least one time in the last year OR&#xD;
&#xD;
          -  ICD10 diagnosis codes (see Appendix A) OR&#xD;
&#xD;
          -  Having diabetes in the patient's medical record problem list&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have diabetes, but no CKD.&#xD;
&#xD;
          -  Are currently on dialysis (ICD 10 codes N18.6, Z99.2 and Z94.0)&#xD;
&#xD;
          -  Have ESRD (eGFR&lt;15 ml/min)&#xD;
&#xD;
          -  Have a terminal illness&#xD;
&#xD;
          -  Have patient-reported known pregnancy at time of enrollment&#xD;
&#xD;
          -  Have had a liver, kidney, or bone marrow transplant&#xD;
&#xD;
          -  Too cognitively impaired to provide informed consent and/or complete the study&#xD;
             protocol&#xD;
&#xD;
          -  Institutionalized or too ill to participate (i.e. incarcerated, psychiatric or nursing&#xD;
             home facility)&#xD;
&#xD;
          -  Plan to move out of the area within 6 months of enrollment&#xD;
&#xD;
          -  Not a current patient seeing a provider who cares for their hypertension (i.e., family&#xD;
             medicine, internal medicine, nephrology, HIV provider, cardiology, hypertension&#xD;
             specialists) at a participating site&#xD;
&#xD;
          -  Previously participated in the GUARDD pilot study OR have previously undergone APOL1&#xD;
             testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hrishikesh Chakraborty</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teji Rakhra-Burris</last_name>
    <phone>919-684-9849</phone>
    <email>teji.rb@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Florida (Gainesville and Jacksonville)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Elwood</last_name>
      <phone>352-273-6007</phone>
      <email>erica.elwood@cop.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Rhonda Cooper-DeHoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheryl Lynch</last_name>
      <phone>317-274-2765</phone>
      <email>slynch@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Eadon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianne Voros</last_name>
      <phone>504-702-3143</phone>
      <email>Brianne.Voros@lcmchealth.org</email>
    </contact>
    <investigator>
      <last_name>Jyotsna Fuloria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Ramos</last_name>
      <phone>212-659-9571</phone>
      <email>michelle.ramos@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Carol Horowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Institute for Family Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nandini Shroff</last_name>
      <phone>212-633-0800</phone>
      <phone_ext>1363</phone_ext>
      <email>Nshroff@institute.org</email>
    </contact>
    <investigator>
      <last_name>Neil Calman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southeastern Healthcare</name>
      <address>
        <city>Lumberton</city>
        <state>North Carolina</state>
        <zip>28358</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asa A Revels, PhD</last_name>
      <phone>910-775-4145</phone>
    </contact>
    <investigator>
      <last_name>Joseph Roberts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meharry Medical College</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajbir Singh</last_name>
      <phone>615-327-6204</phone>
      <email>henry.h.ong@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Rajbir Singh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry Ong</last_name>
      <phone>615-322-5000</phone>
      <email>henry.h.ong@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Kerri Cavanaugh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aisha Montgomery</last_name>
      <phone>214-865-3071</phone>
      <email>Aisha.Montgomery@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Heather Kitzman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

